The significance of α-synuclein, amyloid-β and tau pathologies in parkinson's disease progression and related dementia

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 154-156

  Compta, Yaroslau ^a   Parkkinen, Laura ^c   Kempster, Peter ^b   Selikhova, Mariana ^d   Lashley, Tammaryn ^d   Holton, Janice L ^d   Lees, Andrew J ^d   Revesz, Tamas ^d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Synuclein; Alzheimer type pathology; Amyloid ; Biomarkers; Dementia; Lewy type pathology; Parkinson's disease; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ARTICLE; BRAIN ATROPHY; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; HUMAN; LIMBIC SYSTEM; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; CONFERENCE PAPER; LEWY BODY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; SYSTEMATIC REVIEW (TOPIC);

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BRAIN; DEMENTIA; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; TAU PROTEINS;

EID: 84896840327     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000354670     Document Type: Article

References (28)

1. Hely MA, Reid WG, Adena MA, et al: The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
2. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
3. Evans J, Revesz T, Barker RA: Lesions associated with cognitive impairment and dementia; in Halliday G, Barker RA, Rowe D: Non-Dopamine Lesions in Parkinson's Disease. Oxford, Oxford University Press, 2011.
4. Pletnikova O, West N, Lee MK, et al: Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26: 1183-1192.
5. Lashley T, Holton JL, Gray E, et al: Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008; 115: 417-425.
6. Clinton LK, Blurton-Jones M, Myczek K, et al: Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-7289.
7. Guo JL, Covell DJ, Daniels JP, et al: Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 2013; 154: 103-117.
8. Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613.
9. Fagan AM, Mintun MA, Mach RH, et al: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519.
10. Tokuda T, Qureshi MM, Ardah MT, et al: Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 75: 1766-1772.
11. Selikhova M, Williams DR, Kempster PA, et al: A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-2957.
12. Kempster PA, O'Sullivan SS, Holton JL, et al: Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133: 1755-1762.
13. Compta Y, Parkkinen L, O'Sullivan SS, et al: Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011; 134: 1493-1505.
14. Braak H, Del Tredici K, Rub U, et al: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
15. Braak H, Alafuzoff I, Arzberger T, et al: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berlin) 2006; 112: 389-404.
16. Halliday G, Hely M, Reid W, Morris J: The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409-415.
17. Sabbagh MN, Adler CH, Lahti TJ, et al: Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009; 23: 295-297.
18. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK: Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008; 67: 155-161.
19. Irwin DJ, White MT, Toledo JB, et al: Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587-598.
20. Kotzbauer PT, Cairns NJ, Campbell MC, et al: Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol 2012; 69: 1326-1331.
21. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al: Cerebrospinal tau, phospho-tau, and betaamyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009; 24: 2203-2210.
22. Petrou M, Bohnen NI, Muller ML, et al: β-Amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012; 79: 1161-1167.
23. Compta Y, Ibarretxe-Bilbao N, Pereira JB, et al: Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012; 18: 941-947.
24. Shimada H, Shinotoh H, Hirano S, et al: β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013; 28: 169-175.
25. Siderowf A, Xie SX, Hurtig H, et al: CSF amyloid-beta 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75: 1055-1061.
26. Compta Y, Pereira JB, Rios J, et al: Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013; 19: 717-724.
27. Prikrylova Vranova H, Mares J, Hlustik P, et al: Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. J Neural Transm 2012; 119: 353-362.
28. Müller ML, Frey KA, Petrou M, et al: β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013; 28: 296-301.